Lucid-MS enters phase 2: can it really protect myelin?

The FDA cleared a phase 2 trial of Lucid-MS in progressive MS. Here is how PAD2 inhibition may protect myelin, what is proved, and why this is not yet an approved drug.

When a headline says “historic first treatment could reshape a multibillion-dollar market”, it is easy to hear only one word: hope. As someone living with MS, I hear it too. But with an experimental drug, the most important job is separating what has actually happened from what still has to be proved.

The real event matters: the US Food and Drug Administration accepted Quantum BioPharma’s Investigational New Drug application and cleared a randomised, double-blind, placebo-controlled phase 2 trial of Lucid-MS, also called Lucid-21-302, in progressive multiple sclerosis [1](#ref-1). This is permission to test the drug — not approval of the drug, not proof that it works, and not a cure.

Why this approach is different

Most disease-modifying therapies used today primarily reduce or redirect immune activity. They can be very effective at cutting relapses and new inflammatory lesions, but they do not automatically rebuild damaged myelin or restore lost function. Lucid-MS is being developed as an oral neuroprotective drug acting closer to the process of myelin breakdown, without broad immunosuppression [1](#ref-1), [2](#ref-2).

The company describes it as an inhibitor of PAD2, or peptidyl arginine deiminase 2. PAD2 changes proteins through a process called citrullination. One important target is myelin basic protein (MBP), a structural part of the sheath insulating nerve fibres. When MBP is excessively citrullinated, myelin becomes less compact and more vulnerable to breakdown [4](#ref-4), [5](#ref-5).

The idea is attractive: restrain excessive PAD2 activity, preserve myelin structure and give the nervous system a better chance to maintain or recover function. In laboratory and animal models, Lucid-MS has been reported to preserve myelin and accelerate functional recovery. Those are preclinical findings. Mice are not people with progressive MS, and many drugs that look excellent in the laboratory do not show clinical benefit [3](#ref-3).

What phase 1 tells us

Two phase 1 studies, involving 56 healthy volunteers in total, were completed before this clearance: one tested single ascending doses and the other multiple ascending doses. Their purpose was not to show benefit in MS. They examined safety, tolerability and how the body absorbs and processes the compound [6](#ref-6), [7](#ref-7).

So we still have no clinical answer to the questions that matter most: does Lucid-MS slow disability progression, does it preserve myelin in the human brain and spinal cord, how durable might any effect be, and what risks appear with longer treatment?

What phase 2 must prove

The announced study focuses on progressive MS, where unmet need remains greatest. Randomisation and a placebo group are meant to show whether any difference is genuinely caused by the drug rather than natural symptom fluctuation, expectations or patient selection. Double blinding means neither participants nor investigators know who receives the drug until the data are unlocked.

For me, the value of the result will turn on four points: a clearly defined primary outcome; confirmed disability progression rather than only a laboratory marker; imaging evidence of myelin preservation or repair; and follow-up long enough to detect both benefit and harm. Until the full protocol and recruitment plan appear in a public registry, caution is warranted.

An important nuance: PAD2 is not simply a “bad enzyme”

Biology rarely works like an on-off switch. Research links increased MBP citrullination and altered PAD2 activity with unstable myelin in MS [4](#ref-4), [5](#ref-5). Other work shows PAD2 also participates in normal oligodendrocyte maturation — the cells that make myelin [8](#ref-8). Dose, location and timing therefore matter. Phase 2 is not merely testing whether PAD2 should be blocked, but whether this molecule can do it precisely and safely enough in people.

Can we finally see myelin, rather than just a lesion?

Alongside Lucid-MS, a separate PET tracer called [18F]3F4AP is being developed. It binds to potassium channels exposed when an axon loses its myelin sheath. Early human studies show different MS lesions can carry different demyelination signals [9](#ref-9), [10](#ref-10). One day this may help researchers measure myelin loss and repair more directly than standard MRI can.

The distinction is essential: [18F]3F4AP is a separate research programme involving Massachusetts General Hospital, Harvard and other centres. There is no confirmation that it forms part of the Lucid-MS trial. It is an example of parallel progress that may eventually help evaluate remyelinating drugs, not evidence that Lucid-MS already rebuilds myelin.

Why the news still matters

People with progressive MS have spent too long hearing that the goal is only to slow what can be slowed. A drug aimed at preserving myelin rather than only suppressing the peripheral immune attack is a genuinely different therapeutic idea. Even if Lucid-MS fails, a well-run trial can tell researchers whether PAD2 is a useful target and how neuroprotection should be measured.

But words such as “first”, “historic” and “revolutionary” in the source material come from company and sponsored communications. They are not the conclusion of an independent expert review. A headline about a multibillion-dollar market is written for investors; patients need the protocol, adverse events, effect size and quality of published data.

What this means for someone with MS today

Do not stop your current treatment or delay rehabilitation while waiting for Lucid-MS. The drug is not available outside clinical research. If recruitment opens, discuss it with your neurologist and read the full informed-consent document: benefit is not guaranteed, placebo is possible, and early risks are not fully known.

Watch three things: registration of the study and its eligibility criteria; independently published results rather than company releases alone; and outcomes that matter in daily life — walking, hand function, fatigue, cognition and confirmed progression. For the current reality of progressive disease, see our guide to [secondary progressive MS](/en/blog/secondary-progressive-multiple-sclerosis-spms-explained-symptoms-diagnosis-treatment), and for what scans can and cannot show, read [what doctors look for on MRI](/en/blog/what-doctors-look-mri-scans-multiple-sclerosis-detailed-guide).

My assessment is cautiously optimistic: this is a serious development worth following, but not a reason to change treatment today. The most honest sentence is: Lucid-MS has earned the chance to prove it can protect myelin; it has not yet proved that it does so in people with MS.

This article is educational and does not replace advice from your neurologist. Lucid-MS is an experimental drug and is not approved to treat multiple sclerosis.